New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide® Diskus®. Study highlights importance of improving treatment ...
Seretide/Advair is GSK’s best-selling drug, and the line was extended in 2003 when the European Union approved the higher-dose 500 Accuhaler for the symptomatic treatment of severe COPD, i.e., ...
GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS®and ADVAIR® DISKUS® in patients with COPD GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, ...
Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate (Seretide™ or Advair ®) is low. However, when asthma control deteriorates, clinicians may ...
Novartis International AG / AirFluSal® Forspiro® showed superiority at 12 months over Seretide® Diskus® [1] in persistence to treatment . Processed and transmitted by Nasdaq Corporate Solutions. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback